Corvus Pharmaceuticals (CRVS) News Today

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is facing a negative sentiment catalyst after HC Wainwright broadly reduced its earnings forecasts. The revisions suggest analysts expect a slower path to profitability, which is likely weighing on the stock.

• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior report, with a zero-day short-interest ratio. However, the accompanying “NaN” change indicates the data may be incomplete or unreliable, so it provides little actionable insight for investors.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $0.83 from $0.66 and cut its 2027 forecast to a loss of $0.80 from $0.63. Quarterly estimates were also reduced, including Q3 2026 to a $0.23 loss from $0.17 and Q1–Q2 2027 to losses of $0.23 and $0.24, respectively. HC Wainwright earnings estimates
• Negative Sentiment: Longer-term projections also deteriorated: FY2028 EPS was cut to a $0.37 loss from $0.25, FY2029 was revised to a $0.01 loss from $0.07 profit, and FY2030 was reduced to $0.67 from $0.74. These changes indicate that expected earnings improvement and potential profitability may be arriving later than previously anticipated.
• Negative Sentiment: The revisions reinforce existing earnings risk: Corvus most recently reported a quarterly loss of $0.19 per share, missing the $0.16-loss consensus estimate. The company remains unprofitable, and analysts currently expect a full-year loss of approximately $0.74 per share.